The Onco'Zine Dossier

Advertising/Media Partners

View my Flipboard Magazine.


Report a Problem

See any site problems? Let us know if something looks wrong or isn't working. Click here Report a problem


The information contained in Onco'Zine - The International Cancer Network is generally technical in nature and intended for Healthcare Professionals.


Contribute to Onco'Zine - The International Oncology Network by submitting an idea or draft articles to the editor

Join Our Editorial Board!

Are you interested in becoming an Editorial Board member for Onco'Zine - The International Oncology Network and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor or Contributing Authors, please simply contact us Please enclosing a summary of your research interests and relevant expertise within Oncology and Hematology. We look forward to hearing from you.


Media Partner

Media Partner/Advertisement

Blog Posts

Combined Gene Transduction and Light Therapy Targets Gastric Cancer

Posted by Editorial Team on March 15, 2016 at 1:00pm 0 Comments

Researchers from the Okayama University in Japan report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the February 2016 edition of the journal Small Molecule Therapeutics in February 2016. 

“Gastric cancer is one of the most common malignancies worldwide, making it the third leading cause of cancer-related death,” explain…


Study shows ‘Nano-sensing’ drives Melanoma cells’ Invasion

Posted by Editorial Team on March 14, 2016 at 11:00am 0 Comments

A new study supported by funding from the National Institutes of Health and the Yale Cancer Center sheds light on how melanoma cells change from benign to malignant, and how the complex interaction between the cells and their surrounding environment affects outcomes of the cancer.

The transition from the radial growth patterns of benign melanoma cells to the vertical patterns of malignant cells has long been a mystery to researchers. But a study from the lab of Andre Levchenko, the…


Researchers are Studying Cardiac Drugs that Also Attack Cancer

Posted by Editorial Team on March 11, 2016 at 12:30pm 0 Comments

Several drugs now being used to treat heart failure and atrial arrhythmia also show promise as DNA disruptors in cancer cells and could be readily repurposed as anticancer agents, according to a new study by Yale researchers which was supported by the National Institute of General Medical Sciences, CureSearch for Children’s Cancer, and the Yale Center for Molecular Discovery.

Cardiac glycosides, which are bioactive natural products found in certain plants and insects, aid in cardiac…


Early Diagnosis: A Paradigm Shift in How we Think About and Approach Cancers

Posted by Editorial Team on March 11, 2016 at 9:30am 0 Comments

Contributing Editors: Amit Kumar, Ph.D and Robert Berman

For nearly 45 years, the national dialogue, when it comes to cancers, has remained essentially the same. We have been racing for the cure, praying for the cure, searching for the cure, researching for the cure, raising money for the cure, funding the cure, and developing treatments for the cure. Curing cancer has become the “national cancer objective”.…


Industry Visionaries Meet to Explore New Combination Cancer Drug Development Paradigm

Posted by Editorial Team on March 7, 2016 at 2:00pm 0 Comments

Senior leaders from more than a dozen biopharmaceutical companies came together today with world-class academic clinicians from four leading cancer centers, representatives from oncology non-profits, the FDA, and other key stakeholder organizations to advance the most promising avenues for curing cancer: accelerating the development of investigational drug combination therapies of two or more investigational treatments which may hold great promise for cancer patients. 

The endeavor,…


ASCO GI: Establishing Abraxane® + gemcitabine as the Foundation for Research in First-line Metastatic Pancreatic Cancer

Posted by Editorial Team on February 1, 2016 at 10:00pm 0 Comments

Located just behind the stomach, measuring about 6 inches long and less than 2 inches wide, is an organ called the pancreas. Shaped like a fish with a wide head, a tapering body and a small, pointed tail, the pancreas contains 2 different types of glands - exocrine and endocrine - which are a vital part of the digestive system and a critical controller of blood sugar levels.

Tumors of the pancreas are malignant neoplasms arising in the pancreas. Because of its 'hidden' location, these…


Oasmia Confirms Data Suggesting Equal Efficacy for Novel Therapeutic Paclical® and US-Approved Abraxane®

Posted by Editorial Team on January 22, 2016 at 8:30pm 0 Comments

By Sonia Portillo, Medical Writer

In the current oncology therapeutics market, an estimated $45 billion is brought in through cytogenic therapeutics. Of that amount, 70% is attributed to generic cytostatics, which are largely dominated by paclitaxel-based products Taxol and Abraxane® (Celgene). In fact, before going generic, Taxol brought in around 1.6 billion dollars annually, and it was used for 16 cancer indexes. Just last…


Asbestos: Still A Threat Today

Posted by Editorial Team on December 18, 2015 at 9:00am 0 Comments

Although the United States has curtailed the use of asbestos-containing products in residential and commercial construction, the effects of asbestos exposure are still a major concern. Additionally, there are several places around the world where asbestos exposure is still quite high. Asbestos occurs naturally in the ground in countries like Turkey.…


Changes in Cervical Cancer Stage at Diagnosis and Initial Treatment Among Young Women Before and After ACA

Posted by Editorial Team on November 24, 2015 at 10:30am 0 Comments

Although based on early data, study findings suggest an association between the Affordable Care Act Dependent Coverage Expansion provision and cervical cancer stage at diagnosis and receipt of fertility-sparing treatment among young women age 21 to 25 years, but not among women aged 26 to 34 years, according to a study, supported by the Intramural Research Department of the American Cancer Society, published in the November 24 issue of JAMA.

In September 2010,…


New Engineered Material May Advance Bone-grafting Treatments For Cancer Patients

Posted by Editorial Team on November 19, 2015 at 9:00am 0 Comments

Biomedical engineers at Texas A&M University, committed to solving the world’s greatest health problems through the exploration of new ideas, integrated research and innovation, have developed a new technology focusing on a new synthetic material that’s strong enough to fill gaps in bone while stimulating new bone growth that could advance the grafting treatments needed by people suffering from bone cancer and other bone defects.

"This material serves as a biodegradable scaffold…



  • Add Photos
  • View All

Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



Meet us on Facebook

© 2016   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+